Containment Genetic Disease Scientist 
XTalks
NOVEMBER 10, 2020
Expeditious and accurate diagnoses are necessary for patients to access healthcare services and treatment options for rare genetic diseases. Increasing the efficiency of case analysis and interpretation is essential to providing timely care for patients with genetic diseases.
The Pharma Data
OCTOBER 18, 2020
Telomeres degrade and shorten with age and can become excessively damaged in certain genetic diseases, as well as from lifestyle factors such as smoking, poor diet, and chronic stress. Shortening of telomeres is associated with the symptoms of aging, heart disease, DNA damage and uncontrolled cell replication, which can lead to cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 18, 2023
In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy.
XTalks
MAY 4, 2021
While epigenetic therapies such as DNA methyltransferase (DNMT) inhibitors like azacitadine are used as hypomethylating agents in the treatment of diseases like myelodysplastic syndrome and sometimes in AML, CRISPRoff is the first molecular-based epigenetic tool that could modulate the epigenome to treat disease. pyogenes dCas9.
pharmaphorum
SEPTEMBER 9, 2020
Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. He is currently the patient advocacy and engagement lead at Congenica, a digital health company that is investigating the genetic basis of rare diseases.
XTalks
MAY 4, 2021
While epigenetic therapies such as DNA methyltransferase (DNMT) inhibitors like azacitadine are used as hypomethylating agents in the treatment of diseases like myelodysplastic syndrome and sometimes in AML, CRISPRoff is the first molecular-based epigenetic tool that could modulate the epigenome to treat disease. pyogenes dCas9.
pharmaphorum
SEPTEMBER 9, 2020
Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. He is currently the patient advocacy and engagement lead at Congenica, a digital health company that is investigating the genetic basis of rare diseases.
Expert insights. Personalized for you.
98 
Let's personalize your content